Cancer Gene Discovery Utilizing Sleeping Beauty Transposon Mutagenesis

Author(s):  
Kelsie L. Becklin ◽  
Branden A. Smeester ◽  
Branden S. Moriarity
2015 ◽  
Vol 5 (12) ◽  
pp. 2903-2911 ◽  
Author(s):  
Colleen M. Elso ◽  
Edward P. F. Chu ◽  
May A. Alsayb ◽  
Leanne Mackin ◽  
Sean T. Ivory ◽  
...  

Cell Cycle ◽  
2005 ◽  
Vol 4 (12) ◽  
pp. 1744-1748 ◽  
Author(s):  
Timothy K. Starr ◽  
David A. Largaespada

2021 ◽  
pp. canres.0356.2021
Author(s):  
Michiko Kodama ◽  
Hiroko Shimura ◽  
Jean C Tien ◽  
Justin Y Newberg ◽  
Takahiro Kodama ◽  
...  

2006 ◽  
Vol 15 (suppl_1) ◽  
pp. R75-R79 ◽  
Author(s):  
Adam J. Dupuy ◽  
Nancy A. Jenkins ◽  
Neal G. Copeland

2019 ◽  
Author(s):  
Charlotte R. Feddersen ◽  
Lexy S. Wadsworth ◽  
Eliot Y. Zhu ◽  
Hayley R. Vaughn ◽  
Andrew P. Voigt ◽  
...  

AbstractThe introduction of genome-wide shRNA and CRISPR libraries has facilitated cell-based screens to identify loss-of-function mutations associated with a phenotype of interest. Approaches to perform analogous gain-of-function screens are less common, although some reports have utilized arrayed viral expression libraries or the CRISPR activation system. However, a variety of technical and logistical challenges make these approaches difficult for many labs to execute. In addition, genome-wide shRNA or CRISPR libraries typically contain of hundreds of thousands of individual engineered elements, and the associated complexity creates issues with replication and reproducibility for these methods. Here we describe a simple, reproducible approach using the Sleeping Beauty transposon system to perform phenotypic cell-based genetic screens. This approach employs only three plasmids to perform unbiased, whole-genome transposon mutagenesis. We also describe a ligation-mediated PCR method that can be used in conjunction with the included software tools to map raw sequence data, identify candidate genes associated with phenotypes of interest, and predict the impact of recurrent transposon insertions on candidate gene function. Finally, we demonstrate the high reproducibility of our approach by having three individuals perform independent replicates of a mutagenesis screen to identify drivers of vemurafenib resistance in cultured melanoma cells. Collectively, our work establishes a facile, adaptable method that can be performed by labs of any size to perform robust, genome-wide screens to identify genes that influence phenotypes of interest.


2017 ◽  
Vol 114 (25) ◽  
pp. E4951-E4960 ◽  
Author(s):  
Cristina Montero-Conde ◽  
Luis J. Leandro-Garcia ◽  
Xu Chen ◽  
Gisele Oler ◽  
Sergio Ruiz-Llorente ◽  
...  

Oncogenic RAS mutations are present in 15–30% of thyroid carcinomas. Endogenous expression of mutant Ras is insufficient to initiate thyroid tumorigenesis in murine models, indicating that additional genetic alterations are required. We used Sleeping Beauty (SB) transposon mutagenesis to identify events that cooperate with HrasG12V in thyroid tumor development. Random genomic integration of SB transposons primarily generated loss-of-function events that significantly increased thyroid tumor penetrance in Tpo-Cre/homozygous FR-HrasG12V mice. The thyroid tumors closely phenocopied the histological features of human RAS-driven, poorly differentiated thyroid cancers. Characterization of transposon insertion sites in the SB-induced tumors identified 45 recurrently mutated candidate cancer genes. These mutation profiles were remarkably concordant with mutated cancer genes identified in a large series of human poorly differentiated and anaplastic thyroid cancers screened by next-generation sequencing using the MSK-IMPACT panel of cancer genes, which we modified to include all SB candidates. The disrupted genes primarily clustered in chromatin remodeling functional nodes and in the PI3K pathway. ATXN7, a component of a multiprotein complex with histone acetylase activity, scored as a significant SB hit. It was recurrently mutated in advanced human cancers and significantly co-occurred with RAS or NF1 mutations. Expression of ATXN7 mutants cooperated with oncogenic RAS to induce thyroid cell proliferation, pointing to ATXN7 as a previously unrecognized cancer gene.


Sign in / Sign up

Export Citation Format

Share Document